Is there treatment available?

Augmentation Therapy

Augmentation therapy for Alpha-1 Associated Emphysema

Augmentation therapy has been approved by the FDA for the treatment of Alpha-1 associated emphysema.3

  • Intravenous administration of human alpha1 antitrypsin concentrate has been shown to raise serum levels in people with Alpha-15
    • The hypothesis that augmentation therapy will prevent further lung damage has never been tested in an adequately powered, randomized, controlled clinical trial
  • Studies have also shown that alpha1 antitrypsin augmentation therapy is safe, with few and generally mild side effects6
  • In clinical studies of Zemaira, 1% of subjects reported mild adverse reactions related to treatment, including the following:
    • Fatigue
    • Injection-site pain
    • Dizziness
    • Headache
    • Tingling
    • Itching
Other Supportive Measures

The Zemaira Difference

Find out more about the benefits of Zemaira

Read More

Do I Have Alpha-1?

A simple questionnaire that encourages patients to talk to their doctor about getting tested for Alpha-1

Read More

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.